Ambrx Biopharma Net Income 2020-2021 | AMAM

Ambrx Biopharma net income from 2020 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Ambrx Biopharma Annual Net Income
(Millions of US $)
2020 $-17
2019 $-20
Ambrx Biopharma Quarterly Net Income
(Millions of US $)
2021-06-30
2020-12-31
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.322B $0.014B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.808B 8.01
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $6.887B 0.00
Arcus Biosciences (RCUS) United States $3.210B 0.00
Emergent Biosolutions (EBS) United States $2.270B 8.16
Myovant Sciences (MYOV) United Kingdom $1.508B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.469B 0.00
Zymeworks (ZYME) Canada $0.850B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Enzo Biochem (ENZ) United States $0.170B 16.71